Taylor-Papadimitriou J - Search Results

1

Breast cancer and the immune system: opportunities and pitfalls.

Plunkett TA, Correa I, Miles DW, Taylor-Papadimitriou J. Plunkett TA, et al. J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):467-75. doi: 10.1023/a:1014743232598. J Mammary Gland Biol Neoplasia. 2001. PMID: 12013535 Review.

2

MUC1 and the immunobiology of cancer.

Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M. Taylor-Papadimitriou J, et al. J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21. doi: 10.1023/a:1020360121451. J Mammary Gland Biol Neoplasia. 2002. PMID: 12463741 Review.

3

Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, Finn OJ. Correa I, et al. Immunology. 2003 Jan;108(1):32-41. doi: 10.1046/j.1365-2567.2003.01562.x. Immunology. 2003. PMID: 12519300 Free PMC article.

4

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.

Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, Rubens RD. Miles DW, et al. Br J Cancer. 1996 Oct;74(8):1292-6. doi: 10.1038/bjc.1996.532. Br J Cancer. 1996. PMID: 8883420 Free PMC article. Clinical Trial.

5

Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.

Miles DW, Taylor-Papadimitriou J. Miles DW, et al. Pharmacol Ther. 1999 Apr;82(1):97-106. doi: 10.1016/s0163-7258(99)00003-0. Pharmacol Ther. 1999. PMID: 10341360 Review.

6

MUC1 and cancer.

Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. Taylor-Papadimitriou J, et al. Biochim Biophys Acta. 1999 Oct 8;1455(2-3):301-13. doi: 10.1016/s0925-4439(99)00055-1. Biochim Biophys Acta. 1999. PMID: 10571020 Free article. Review.

7

Mucin based breast cancer vaccines.

Miles DW, Taylor-Papadimitriou J. Miles DW, et al. Expert Opin Investig Drugs. 1998 Nov;7(11):1865-77. doi: 10.1517/13543784.7.11.1865. Expert Opin Investig Drugs. 1998. PMID: 15991935

8

Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain.

Plunkett T, Graham R, Correa I, Sewell R, Miles D, Burchell J, Taylor-Papadimitriou J. Plunkett T, et al. Int J Cancer. 2004 May 1;109(5):691-7. doi: 10.1002/ijc.20040. Int J Cancer. 2004. PMID: 14999776

9

T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients.

Coleman JA, Correa I, Cooper L, Bohnenkamp HR, Poulsom R, Burchell JM, Taylor-Papadimitriou J. Coleman JA, et al. Int J Cancer. 2011 May 1;128(9):2114-24. doi: 10.1002/ijc.25792. Epub 2011 Feb 11. Int J Cancer. 2011. PMID: 21105039

10

Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin.

Nath D, Hartnell A, Happerfield L, Miles DW, Burchell J, Taylor-Papadimitriou J, Crocker PR. Nath D, et al. Immunology. 1999 Oct;98(2):213-9. doi: 10.1046/j.1365-2567.1999.00827.x. Immunology. 1999. PMID: 10610356 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

264 results

Search Page

Filters